At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 509 enrolled
Drug / intervention
pregabalin +1 moredrug
Likely dose
pregabalin 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Parallel-Group Multi-Center Comparative Flexible-Dose Study Of Pregabalin Versus Levetiracetam As Adjunctive Therapy To Reduce Seizure Frequency In Subjects With Partial Seizures
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Oct 1, 2007·Updated Jan 28, 2021
In Brief
A Phase 3 clinical trial evaluating pregabalin and levetiracetam for Partial Seizures. Completed, enrolled 509 participants across 72 sites in 21 countries.
Detailed Summary
This study will compare pregabalin and levetiracetam in patients with partial seizures. It will also evaluate the safety and tolerability of pregabalin and levetiracetam in these patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPartial Seizures
CountriesBelgium, Bulgaria, Colombia, Costa Rica, Czechia, France, Germany, Greece, India, Italy, Lithuania, Mexico, Panama, Peru, Philippines, Russia, South Korea, Spain, Taiwan, Turkey (Türkiye), Venezuela
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2007
Enrollment StartOct 2007
Primary CompletionMay 2012
TodayJul 2026
First PostedOct 1, 2007
Enrollment StartOct 1, 2007
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 18.8 years ago
Interventions
pregabalindrug
300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
levetiracetamdrug
1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects